Genentech is shedding even more employees

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. We await one of the year’s biggest biotech readouts, and have lots of GLP-1 news today: Eli Lilly’s offer to slash pricing for Zepbound isn’t as magnanimous as it appears, and more.

Hims GLP-1 strategy could invite backlash from FDA, drugmakers

The wildly popular telehealth company Hims & Hers has been offering compounded versions of GLP-1 weight loss drugs, amid shortages of FDA-approved versions. The company, which has expanded aggressively, plans to continue selling GLP-1s even after the shortages end.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In